Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria - All Patients: * Male or female patients ≥18 years of age * Histologically confirmed incurable or metastatic solid tumors that are HPV16+ (performed during screening locally or centrally, or based on documented historic test results) * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1 * At least 1 measurable lesion according to RECIST 1.1 * Must have a lesion that can be biopsied with acceptable clinical risk and agree to have a fresh biopsy at Screening and on Cycle 2 Day 8 (+/- 2 days) * Patients must agree to venous access for leukapheresis and be willing to have a central line inserted if venous access is an issue * Adequate organ function and bone marrow reserve performed within 14 days prior to leukapheresis Inclusion Criteria - Part 2: • Patients must not have been treated with immune check-point inhibitors Exclusion Criteria - All Patients: * Treatment with anticancer therapy, including investigational therapy, within 2 weeks prior to leukapheresis. * Systemic treatment with either corticosteroids (\>10 mg of prednisone or the equivalent per day) or other immunosuppressive medications within 14 days prior to leukapheresis * Patients treated with non-corticosteroid based immunosuppressive agents within the last 6 months prior to leukapheresis * Patients with active, known, or suspected autoimmune disease may not be eligible and should be discussed with the Sponsor * Patients with \>Grade 1 AEs related to previous treatment with anticancer or investigational therapy that do not resolve at least 2 weeks prior to leukapheresis, except Grade 2 neuropathy, ototoxicity, mucositis, fatigue, alopecia, or endocrine disorders managed with hormone replacement * Known HIV infection, active hepatitis B or hepatitis C, or active mycobacterium tuberculosis infection * Has known active central nervous system metastases * Have active interstitial lung disease and any history of myocarditis * Major surgery within 2 weeks of leukapheresis Exclusion Criteria - Part 1B: * Known hypersensitivity to pembrolizumab * History of any Grade 3 immune-related AE (irAE) from prior immunotherapy Exclusion Criteria - Part 2: • Prior treatment with an immune check-point inhibitor